Please login to the form below

Not currently logged in
Email:
Password:

Pfizer launch grants programme for cardiovascular research

PCSK9 initiative is an extension of existing ASPIREprogramme

Pfizer logo 

Pfizer has revealed a new competitive grants programme to support research projects investigating the role of PCSK9 in health and cardiovascular disease.

The programme, which is an extension of the Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) cardiovascular programme, adds to Pfizer's on going commitment related to scientific discoveries in the field.

Rory O'Connor, senior VP of global medical affairs at Pfizer, commented: “Our development of the ASPIRE cardiovascular competitive grants programme aligns with a key area of focus for Pfizer; advancing the science, finding and developing new medicines that will treat – and ultimately may prevent – cardiovascular disease.”

The first annual ASPIRE cardiovascular competitive grants programme will fund multiple grants of up to $100,000 each to support the discovery of new insights in the role of PCSK9 in health and disease.

Grantees will be selected through an applications process overseen by an independent review committee chaired by Professor John Chapman, director emeritus of the dyslipidemia and atherosclerosis research unit of the National Institute for Health and Medical Research (INSERM) at the Pitié-Salpétrière University Hospital in Paris.

The review committee has highlighted specific research areas of interest, including vascular biology, PCSK9 and the immune system and non lipid and lipoprotein effects of PCSK9.

Professor Chapman added: “One of the most exciting new areas for scientific exploration in cardiovascular disease is focused on PCSK9.

“It is our earnest desire that the research projects selected will advance the current understanding of PCSK9 biology and in this way, contribute significantly to the next generation of potential therapies targeted to cardiovascular diseases.”

In 2014, Pfizer and BMS donated a combined $1m to non-profit organisations to support patients with cardiovascular diseases.

Article by
Kirstie Pickering

12th April 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics